Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma

about

Clinical Benefit of Pazopanib in a Patient with Metastatic Chondrosarcoma: A Case Report and Review of the Literature.Response to PD1 inhibition in conventional chondrosarcoma

P2860

Q52652949-12D8A0F9-F013-4413-9696-916B8ED0D2A5 Q58698493-7DF0E339-5798-4689-AF07-C448D7760B41

P2860

Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma

Item

http://www.wikidata.org/entity/Q38602635

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma

@en

type

Item

label

Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma

@en

prefLabel

Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma

@en

P1476

Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma

@en

P2093

Daniela Katz

http://www.w3.org/2001/XMLSchema#string

Darin Davidson

http://www.w3.org/2001/XMLSchema#string

Elizabeth T Loggers

http://www.w3.org/2001/XMLSchema#string

Eve T Rodler

http://www.w3.org/2001/XMLSchema#string

Seth M Pollack

http://www.w3.org/2001/XMLSchema#string

P2860

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo.

Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.

The clinical approach towards chondrosarcoma.

Analysis of angiogenic factors and cyclooxygenase-2 expression in cartilaginous tumors- clinical and histological correlation

Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis.

Advanced chondrosarcomas: role of chemotherapy and survival.

Ramucirumab: a novel antiangiogenic agent.

Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy.

P2888

s12032-017-1030-2

P304

167

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12032-017-1030-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Robin L Jones

P577

2017-08-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1091389329

http://www.w3.org/2001/XMLSchema#string

P698

28852958

http://www.w3.org/2001/XMLSchema#string

P921

chondrosarcoma

P932

5574947

http://www.w3.org/2001/XMLSchema#string

Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma

about

P2860

P2860

Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P921

P932